Vancouver, B.C. - TheNewswire - April 27, 2021  –  Solarvest BioEnergy Inc. (“Solarvest”, or the “Company”) (TSXV:SVS) (“Solarvest” or the “Company”), announces that it has been granted patents in Australia and India.  The intellectual property protection concentrates on the production of algal biomass, algal cell cultures, lipid compounds, and compositions thereof, including fatty acids, carotenoids and fat soluble vitamins.  These patents add additional strength to the Company’s existing patent portfolio as it commercializes its line of organic Omega-3 products.  

After its initial product launch and further industry discussions, the Company has focused on supplying unique “clean label” products to satisfy the demand for premium plant-based, organic Omega-3 health products.  In addition, the Company’s wholly owned subsidiary Eversea has accelerated efforts to offer organic marketing companies and organic oriented retailers with house branded products (often termed “white label”) based on our unique bioavailable Omega-3 ingredient. Channel marketing feedback indicates that there is extensive market demand for the product’s unique characteristics, particularly among consumers focused on organic and vegan diets.  The Company’s patented Omega-3 active ingredient has obtained FDA NDI (New Dietary Ingredient) certification, and is USDA and EU Organic Certified.  

Further to marketing of Organic Omega-3 in the United States, the team has received substantial interest due to the timely introduction of a premium ingredient when the reality of chemical and heavy metal contamination in baby food has been brought to light.  https://oversight.house.gov/sites/democrats.oversight.house.gov/files/2021-02-04%20ECP%20Baby%20Food%20Staff%20Report.pdf  The versatility of the patented ingredient has enabled the Company to demonstrate various Organic Omega-3 products that can be integrated into existing marketing channels. Organic marketers fully recognize the value of chemical free production as a competitive advantage. Moreover, in terms of intellectual property protection, the IP has been described as a rare commodity in a growing market segment.

About Solarvest

Solarvest BioEnergy Inc. is an algae biologics company whose production platform provides an extremely flexible system capable of producing numerous products from Omega 3 fatty acids to human therapeutic proteins. The company has successfully demonstrated the expression of BMP, a high value therapeutic protein, viral antigens (immune stimulating proteins), and Cecropins (antimicrobial peptide/protein). The company has initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.

For further information contact:

Gerri Greenham, Chief Executive Officer

Phone: (647) 204-4095

Email: invest@solarvest.ca

Forward-Looking Information

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the terms of the Offering, the completion of the Offering and the expected use of the net proceeds received by the Company. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including but not limited to: general business, economic, competitive, geopolitical and social uncertainties; and regulatory risks. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking information contained in this news release is expressly qualified in its entirety by this cautionary statement. The Company does not undertake to update any forward-looking information, except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

None of the securities of Solarvest have been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law, and may not be offered or sold in the United States or to, or for the account or benefit of, persons in the United States or “U.S. persons” (as such term is defined in Regulation S under the U.S. Securities Act) absent registration or an exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy in the United States nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.